Compare Keysight Technologies Inc (KEYS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Recursion Pharmaceuticals Inc — how do they compare? Keysight Technologies Inc trades at $381.74 (market cap $63.79B), while Recursion Pharmaceuticals Inc trades at $4.24 (market cap $2.14B). The key difference: Keysight Technologies Inc is far larger — about 29.8× Recursion Pharmaceuticals Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 56 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| KEYS | RXRX | |
|---|---|---|
Market Cap | $63.79B | $2.14B |
Volume | 1,435,384 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $387.90 | $6.79 |
52-Week Low | $159.49 | $2.84 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | $63.93B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $382.75, up 0.33% with strong technical momentum as it approaches resistance at $385. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $3.07 versus $2.48, supported by 19.14% net margins and 20.59% ROE. Recent news highlights AI infrastructure demand and 6G development opportunities, with orders surging 56% in Q3 2026.
Wall Street maintains strong bullish sentiment with 81% buy ratings and $416.63 consensus target, though elevated P/E of 50.7 presents valuation risk. Growth catalysts include AI data-center expansion and 6G wireless development, while risks involve supply constraints and competitive pressures in the testing equipment market.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
